The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Sixty-three percent of patients starting on Novo Nordisk's Wegovy or Eli Lilly's Zepbound during the first quarter of 2024 ...

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in ...

Wegovy will now be the GLP-1 weight loss drug of choice under plans that are managed by CVS Caremark. If they stay on Zepbound for their GLP-1 weight loss treatment, they will have to pay full ...

Wegovy received U.S. Food and Drug Administration (FDA) approval and was launched in June 2021, and Zepbound entered the market in December 2023 as a new contender.

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.